|
Gene: CERS4 |
Gene summary for CERS4 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CERS4 | Gene ID | 79603 |
Gene name | ceramide synthase 4 | |
Gene Alias | LASS4 | |
Cytomap | 19p13.2 | |
Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q53HF9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79603 | CERS4 | SYSMH1 | Human | Oral cavity | OSCC | 2.18e-17 | 4.15e-01 | 0.1127 |
79603 | CERS4 | SYSMH2 | Human | Oral cavity | OSCC | 3.61e-18 | 6.45e-01 | 0.2326 |
79603 | CERS4 | SYSMH3 | Human | Oral cavity | OSCC | 1.36e-29 | 8.94e-01 | 0.2442 |
79603 | CERS4 | SYSMH5 | Human | Oral cavity | OSCC | 6.42e-03 | 1.83e-01 | 0.0647 |
79603 | CERS4 | SYSMH6 | Human | Oral cavity | OSCC | 2.15e-06 | 3.17e-01 | 0.1275 |
79603 | CERS4 | P4_S8_cSCC | Human | Skin | cSCC | 9.32e-04 | 1.69e-01 | -0.3095 |
79603 | CERS4 | P1_cSCC | Human | Skin | cSCC | 2.78e-16 | 6.29e-01 | 0.0292 |
79603 | CERS4 | P2_cSCC | Human | Skin | cSCC | 1.57e-04 | 2.22e-01 | -0.024 |
79603 | CERS4 | P4_cSCC | Human | Skin | cSCC | 7.57e-11 | 3.84e-01 | -0.00290000000000005 |
79603 | CERS4 | cSCC_p8 | Human | Skin | cSCC | 7.98e-03 | 2.10e-01 | -0.1971 |
79603 | CERS4 | cSCC_p9 | Human | Skin | cSCC | 2.25e-04 | 2.16e-01 | -0.1991 |
79603 | CERS4 | male-WTA | Human | Thyroid | PTC | 3.05e-27 | 2.23e-01 | 0.1037 |
79603 | CERS4 | PTC01 | Human | Thyroid | PTC | 5.40e-24 | 5.76e-01 | 0.1899 |
79603 | CERS4 | PTC04 | Human | Thyroid | PTC | 7.71e-16 | 3.16e-01 | 0.1927 |
79603 | CERS4 | PTC05 | Human | Thyroid | PTC | 4.33e-25 | 9.85e-01 | 0.2065 |
79603 | CERS4 | PTC06 | Human | Thyroid | PTC | 1.56e-31 | 8.47e-01 | 0.2057 |
79603 | CERS4 | PTC07 | Human | Thyroid | PTC | 3.19e-43 | 8.87e-01 | 0.2044 |
79603 | CERS4 | ATC13 | Human | Thyroid | ATC | 9.90e-21 | 3.42e-01 | 0.34 |
79603 | CERS4 | ATC5 | Human | Thyroid | ATC | 2.13e-17 | 3.63e-01 | 0.34 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
GO:00464673 | Esophagus | ESCC | membrane lipid biosynthetic process | 91/8552 | 142/18723 | 7.19e-06 | 7.19e-05 | 91 |
GO:00066652 | Esophagus | ESCC | sphingolipid metabolic process | 96/8552 | 155/18723 | 3.21e-05 | 2.66e-04 | 96 |
GO:00301481 | Esophagus | ESCC | sphingolipid biosynthetic process | 62/8552 | 103/18723 | 2.10e-03 | 9.38e-03 | 62 |
GO:00066721 | Esophagus | ESCC | ceramide metabolic process | 61/8552 | 102/18723 | 2.82e-03 | 1.19e-02 | 61 |
GO:0046513 | Esophagus | ESCC | ceramide biosynthetic process | 40/8552 | 65/18723 | 7.25e-03 | 2.63e-02 | 40 |
GO:00066431 | Liver | HCC | membrane lipid metabolic process | 115/7958 | 203/18723 | 3.17e-05 | 3.22e-04 | 115 |
GO:0006665 | Liver | HCC | sphingolipid metabolic process | 85/7958 | 155/18723 | 1.27e-03 | 6.92e-03 | 85 |
GO:0046467 | Liver | HCC | membrane lipid biosynthetic process | 78/7958 | 142/18723 | 1.85e-03 | 9.46e-03 | 78 |
GO:00066432 | Oral cavity | OSCC | membrane lipid metabolic process | 111/7305 | 203/18723 | 4.02e-06 | 4.69e-05 | 111 |
GO:00066651 | Oral cavity | OSCC | sphingolipid metabolic process | 84/7305 | 155/18723 | 8.64e-05 | 6.61e-04 | 84 |
GO:00464672 | Oral cavity | OSCC | membrane lipid biosynthetic process | 77/7305 | 142/18723 | 1.63e-04 | 1.13e-03 | 77 |
GO:0006672 | Oral cavity | OSCC | ceramide metabolic process | 53/7305 | 102/18723 | 5.28e-03 | 2.06e-02 | 53 |
GO:0030148 | Oral cavity | OSCC | sphingolipid biosynthetic process | 53/7305 | 103/18723 | 6.81e-03 | 2.53e-02 | 53 |
GO:000664311 | Oral cavity | LP | membrane lipid metabolic process | 69/4623 | 203/18723 | 1.77e-03 | 1.34e-02 | 69 |
GO:00464671 | Oral cavity | LP | membrane lipid biosynthetic process | 49/4623 | 142/18723 | 5.44e-03 | 3.31e-02 | 49 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0407116 | Esophagus | ESCC | Sphingolipid signaling pathway | 85/4205 | 121/8465 | 3.04e-06 | 1.73e-05 | 8.84e-06 | 85 |
hsa006003 | Esophagus | ESCC | Sphingolipid metabolism | 36/4205 | 53/8465 | 5.41e-03 | 1.36e-02 | 6.99e-03 | 36 |
hsa0407117 | Esophagus | ESCC | Sphingolipid signaling pathway | 85/4205 | 121/8465 | 3.04e-06 | 1.73e-05 | 8.84e-06 | 85 |
hsa0060012 | Esophagus | ESCC | Sphingolipid metabolism | 36/4205 | 53/8465 | 5.41e-03 | 1.36e-02 | 6.99e-03 | 36 |
hsa040718 | Liver | HCC | Sphingolipid signaling pathway | 72/4020 | 121/8465 | 5.01e-03 | 1.47e-02 | 8.18e-03 | 72 |
hsa00600 | Liver | HCC | Sphingolipid metabolism | 34/4020 | 53/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 34 |
hsa0407111 | Liver | HCC | Sphingolipid signaling pathway | 72/4020 | 121/8465 | 5.01e-03 | 1.47e-02 | 8.18e-03 | 72 |
hsa006001 | Liver | HCC | Sphingolipid metabolism | 34/4020 | 53/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 34 |
hsa0407114 | Oral cavity | OSCC | Sphingolipid signaling pathway | 82/3704 | 121/8465 | 6.97e-08 | 5.08e-07 | 2.58e-07 | 82 |
hsa006002 | Oral cavity | OSCC | Sphingolipid metabolism | 33/3704 | 53/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 33 |
hsa0407115 | Oral cavity | OSCC | Sphingolipid signaling pathway | 82/3704 | 121/8465 | 6.97e-08 | 5.08e-07 | 2.58e-07 | 82 |
hsa0060011 | Oral cavity | OSCC | Sphingolipid metabolism | 33/3704 | 53/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 33 |
hsa0407122 | Oral cavity | LP | Sphingolipid signaling pathway | 48/2418 | 121/8465 | 5.30e-03 | 2.15e-02 | 1.39e-02 | 48 |
hsa0407132 | Oral cavity | LP | Sphingolipid signaling pathway | 48/2418 | 121/8465 | 5.30e-03 | 2.15e-02 | 1.39e-02 | 48 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
CERS4 | ACINAR | Pancreas | ADJ | RBPJL,REG1B,FGFR1, etc. | 3.33e-01 |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CERS4 | SNV | Missense_Mutation | rs781132558 | c.157C>T | p.Arg53Cys | p.R53C | Q9HA82 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
CERS4 | SNV | Missense_Mutation | rs777818786 | c.688N>T | p.Arg230Cys | p.R230C | Q9HA82 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CERS4 | insertion | Nonsense_Mutation | novel | c.2_3insACCCACCTTGGCCTTCTAAAGTGCTGGGATTACAGGCGTGAGCAACTGC | p.Met1? | p.M1? | Q9HA82 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
CERS4 | SNV | Missense_Mutation | rs377204315 | c.1061N>T | p.Ala354Val | p.A354V | Q9HA82 | protein_coding | tolerated(0.24) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CERS4 | insertion | Frame_Shift_Ins | novel | c.104_105insC | p.Gln37ProfsTer21 | p.Q37Pfs*21 | Q9HA82 | protein_coding | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | ||
CERS4 | SNV | Missense_Mutation | rs200803317 | c.92N>A | p.Arg31His | p.R31H | Q9HA82 | protein_coding | tolerated(0.22) | benign(0.071) | TCGA-A6-6650-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CERS4 | SNV | Missense_Mutation | rs775538437 | c.973N>T | p.Arg325Cys | p.R325C | Q9HA82 | protein_coding | deleterious(0.04) | benign(0.133) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CERS4 | SNV | Missense_Mutation | novel | c.1021N>T | p.Arg341Cys | p.R341C | Q9HA82 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CERS4 | SNV | Missense_Mutation | c.227N>T | p.Arg76Met | p.R76M | Q9HA82 | protein_coding | tolerated(0.28) | benign(0.113) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
CERS4 | SNV | Missense_Mutation | novel | c.952N>G | p.Phe318Val | p.F318V | Q9HA82 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |